Literature DB >> 6635438

Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents.

C W Norden.   

Abstract

The efficacy of rifampin alone and in combination with sisomicin, cephalothin, sisomicin and cephalothin, or trimethoprim was measured in an experimental model of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Single-drug regimens used for 28 days were relatively ineffective (bone sterilization rate, 5%-55%). Combinations of rifampin with other agents were more effective (bone sterilization rate, 75%-100%). The combination of rifampin, sisomicin, and cephalothin given for only 14 days sterilized the bones of all treated rabbits. Staphylococci isolated from the bones of rabbits that had received rifampin alone or in combination with other antibiotics were highly resistant to rifampin; in contrast, these organisms remained sensitive to the other agents used. Results of in vitro studies of synergy correlated with in vivo results in some but not all instances. The results obtained with rifampin in the treatment of experimental chronic osteomyelitis caused by S. aureus suggest that clinical trials of this agent for the treatment of osteomyelitis in humans are warranted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635438     DOI: 10.1093/clinids/5.supplement_3.s491

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

Review 1.  Animal models as predictors of the safety and efficacy of antibiotics.

Authors:  O Zak; T O'Reilly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  Bone and joint infections.

Authors:  T Louie
Journal:  Can J Infect Dis       Date:  1992-03

3.  In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.

Authors:  George Pankey; Deborah Ashcraft; Nalini Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Osteomyelitis management: More art than science?

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

5.  Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.

Authors:  R Dworkin; G Modin; S Kunz; R Rich; O Zak; M Sande
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

Authors:  K P Giron; M E Gross; D M Musher; T W Williams; R A Tharappel
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced chronic osteomyelitis with bone defect in rabbits.

Authors:  Ji-Le Jiang; Yun-Fei Li; Tao-Lin Fang; Jian Zhou; Xi-Lei Li; Yi-Chao Wang; Jian Dong
Journal:  Inflamm Res       Date:  2011-12-11       Impact factor: 4.575

8.  Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  Charlene F Dailey; Paul J Pagano; Lewis V Buchanan; Jennifer A Paquette; Joseph V Haas; John K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 9.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Retrospective study of the efficacy of vascularized tissue transfer for treating antibiotic-resistant bacteria-infected wound: Comparison with clean and antibiotic-sensitive bacteria-infected wound.

Authors:  Seong Hwan Kim; Ju Ho Lee; Seong Eun Kim; Se Ho Shin; Hyeon Jo Kim; Seong Joo Lee; Jae Hyun Kim; In Suck Suh
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.